CSIMarket Company Name, Ticker, Industry, else..


Bionexus Gene Lab Corp   (BGLC)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Bionexus Gene Lab Corp

BGLC's Fundamental analysis



Bionexus Gene Lab 's sales fell by -23.07 % in II. Quarter 2024 from the same quarter a year ago. Ranking at No. 1356

Medical Laboratories industry recorded growth of revenues by 0.86 %

Bionexus Gene Lab realized net income compared to net loss a year ago in II. Quarter 2024

• More on BGLC's Growth


Bionexus Gene Lab
realized a net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 1.86 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-0
PE TTM    
Company's Price to Sales ratio is at 0.74.
Medical Laboratories industry's Price to Sales ratio is at 3.22.


• More on BGLC's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 10.41
 Tangible Book Value (Per Share $) 0.54

Bionexus Gene Lab
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 1.86 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-0
PE TTM    
Company's Price to Sales ratio is at 0.74.
Medical Laboratories industry's Price to Sales ratio is at 3.22.

Bionexus Gene Lab Price to Book Ratio is at 0.71 lower than Industry Avg. of 409.18. and higher than S&P 500 Avg. of 0

• More on BGLC's Valuation

•  Market Capitalization (Millions $) 7
•  Shares Outstanding (Millions) 18
•  Employees -
•  Revenues (TTM) (Millions $) 9
•  Net Income (TTM) (Millions $) -2
•  Cash Flow (TTM) (Millions $) 4
•  Capital Exp. (TTM) (Millions $) -1
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ -
•  Net Income/Employee(TTM) $ -
•  Receivable Turnover Ratio (TTM) 10.41
•  Tangible Book Value (Per Share $) 0.54

•  Market Capitalization (Millions $) 7
•  Shares Outstanding (Millions) 18
•  Employees -
•  Revenues (TTM) (Millions $) 9
•  Net Income (TTM) (Millions $) -2
•  Cash Flow (TTM) (Millions $) 4
•  Capital Exp. (TTM) (Millions $) -1


    BGLC's Profitability Comparisons
Bionexus Gene Lab achieved increase in profitability, due to cost control. Operating Margin grew in II. Quarter 2024 to 13.13 %.

Bionexus Gene Lab net profit margin of 10.08 % is currently ranking no. 7 in Medical Laboratories industry, ranking no. 87 in Healthcare sector and number 1134 in S&P 500.


Profitability by Segment
Total 10.08 %



  Ratio
•   Capital Ratio (MRQ) 6.94
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.12
•  Asset Turnover Ratio (TTM) 0.73
•  Inventory Turnover Ratio (TTM) 7.26



Bionexus Gene Lab achieved increase in profitability, due to cost control. Operating Margin grew in II. Quarter 2024 to 13.13 %.

Bionexus Gene Lab net profit margin of 10.08 % is currently ranking no. 7 in Medical Laboratories industry, ranking no. 87 in Healthcare sector and number 1134 in S&P 500.

• More on BGLC's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com